Clinical trials
Carcinoma, Transitional Cell trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Active, not recruiting | 6 |
| Recruiting | 6 |
| Terminated | 3 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 4 |
| The Netherlands Cancer Institute | 4 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 3 |
| Erasmus Medical Center | 3 |
| Hoffmann-La Roche | 3 |
| Bristol-Myers Squibb | 2 |
| Eli Lilly and Company | 2 |
| Incyte Corporation | 2 |
| Alentis Therapeutics AG | 1 |
| Astellas Pharma Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Transitional Cell | 37 |
| Urinary Bladder Neoplasms | 15 |
| Carcinoma, Hepatocellular | 4 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Colorectal Neoplasms | 4 |
| Urologic Neoplasms | 4 |
| Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Carcinoma, Renal Cell | 2 |
Trials
Showing 26 to 37 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.